Barclays analyst Jack Meehan maintained a Hold rating on Charles River Labs (NYSE: CRL) yesterday and set a price target of $120. The company’s shares closed yesterday at $124.18.
According to TipRanks.com, Meehan is a 4-star analyst with an average return of 9.3% and a 64.3% success rate. Meehan covers the Healthcare sector, focusing on stocks such as Genomic Health, Thermo Fisher, and Quidel Corp.
Currently, the analyst consensus on Charles River Labs is a Strong Buy with an average price target of $134.
See today’s analyst top recommended stocks >>
Based on Charles River Labs’ latest earnings release for the quarter ending June 30, the company reported a quarterly net profit of $53.71 million. In comparison, last year the company had a net profit of $53.95 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Charles River Laboratories International, Inc. is an early-stage contract research company, which provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions.
